- Results from a Phase 2a Proof‐of‐Concept Double‐Blind, Randomized, Placebo‐Controlled Trial of Lomecel‐B TM in Mild Alzheimer’s Disease Dementia
- Kevin N. Ramdas - Longeveron Inc., Miami, FL USANataliya Agafonova - Longeveron Inc., Miami, FL USAJoshua M. Hare - Longeveron Inc., Miami, FL USAEric Naioti - Longeveron Inc., Miami, FL USASteven Kopcho - Longeveron Inc., Miami, FL USAJeffrey L. Cummings - University of Nevada, Las VegasRaul Carballosa - First Excellent Research, Miami, FL USAPaayal Patel - Brain Matters ResearchMark Brody - Brain Matters ResearchBrad Herskowitz - Barnstorm ResearchAna Fuquay - Brain Matters ResearchSavannah Rodriguez - Barnstorm ResearchJeffrey Botbyl - Longeveron Inc., Miami, FL USABrian Rash - Longeveron Inc., Miami, FL USAAnthony A. Oliva - Longeveron Inc., Miami, FL USA
- Alzheimer's & dementia, Vol.20(S6)
- Interdisciplinary Stem Cell Institute; Leadership Department; Miller School of Medicine
- English
- Journal article
- 991032523836602976
Results from a Phase 2a Proof‐of‐Concept Double‐Blind, Randomized, Placebo‐Controlled Trial of Lomecel‐B TM in Mild Alzheimer’s Disease Dementia
Alzheimer's & dementia, Vol.20(S6)
2024-12